Sydney Broxton
Psychiatric/Mental Health · Greenville, SCNPI 1538924436
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.
Across 186 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$573
- Otsuka America Pharmaceutical, Inc.$471
- AbbVie$451
- Lundbeck LLC$243
- Takeda Pharmaceuticals U.S.A., Inc.$243
- Corium, LLC$189
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,319100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $573 |
| Otsuka America Pharmaceutical, Inc. | 29 | $471 |
| AbbVie | 37 | $451 |
| Lundbeck LLC | 11 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $243 |
| Corium, LLC | 9 | $189 |
| Axsome Therapeutics, Inc. | 9 | $171 |
| Alkermes, Inc. | 7 | $164 |
| Noven Therapeutics, LLC | 6 | $117 |
| Tris Pharma Inc | 5 | $113 |
| Johnson & Johnson | 4 | $92 |
| Vanda Pharmaceuticals Inc. | 5 | $90 |
| Bausch Health US, LLC | 3 | $70 |
| Neurocrine Biosciences, Inc. | 3 | $56 |
| Ironshore Pharmaceuticals Inc. | 3 | $51 |
| Tonix Medicines, Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Neos Therapeutics, LP | 2 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $27 |
| Harmony Biosciences LLC | 1 | $20 |
How this compares
$3,319 in reported general payments places this provider in the 80th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $330 |
| Fluoxetine Hcl | 15 | $120 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Greenville
- Steven KrozerGreenville$139K
- Luron FlemingGreenville$61K
- Lauren DyerGreenville$16K
- Melissa BrownGreenville$16K
- William HendricksGreenville$13K
- Carrie BallengerGreenville$11K
- Gregory SmithGreenville$9K
- Svetlana RobinsonGreenville$8K
- Jared CarboneGreenville$7K
- Anglique RichGreenville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.